With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
US Generics grew 5% to Rs. 467 Crores for the quarter
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The acquisition is for an enterprise value of Rs. 218 crores
The company will address the observations within a stipulated timeline working with the regulators
Subscribe To Our Newsletter & Stay Updated
